EcoDrugPlus

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSPVAG00000003863
Gene Symbol: PSMA3
1 Cross references
232 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSPVAG00000009182
Gene Symbol: PSMA4
1 Cross references
250 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSPVAG00000008908
Gene Symbol: PSMA5
1 Cross references
210 Possible Orthologues:

Proteasome 20s Subunit Alpha 7

Ensembl ID : ENSPVAG00000017919
Gene Symbol: PSMA7
1 Cross references
155 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSPVAG00000009963
Gene Symbol: PSMA8
1 Cross references
197 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSPVAG00000010819
Gene Symbol: PSMB1
1 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSPVAG00000016612
Gene Symbol: PSMB10
1 Cross references
171 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSPVAG00000001871
Gene Symbol: PSMB2
1 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSPVAG00000002270
Gene Symbol: PSMB3
1 Cross references
234 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSPVAG00000011682
Gene Symbol: PSMB4
1 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSPVAG00000013800
Gene Symbol: PSMB5
1 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSPVAG00000006048
Gene Symbol: PSMB6
1 Cross references
217 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).